Pravastatin: A Review of its Use in Elderly Patients

Drugs and Aging

Volumn 20, Issue 14, 2003, Pages 1061-1082

  Bang, Lynne M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Coronary heart disease; Elderly; Hypercholesterolaemia; Pharmacodynamics; Pharmacokinetics; Pravastatin; Therapeutic use

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; CREATINE KINASE; CYTOCHROME P450 3A4; DILTIAZEM; DRUG METABOLITE; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SQ 31906; SQ 31945; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ELDERLY CARE; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INDIGESTION; ISCHEMIC HEART DISEASE; LETHARGY; LIPOPROTEIN METABOLISM; LIVER DYSFUNCTION; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VERTIGO;

ADULT; AGED; CLINICAL TRIALS; DRUG INTERACTIONS; FEMALE; GERIATRICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PRAVASTATIN; TISSUE DISTRIBUTION;

EID: 0348109329     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320140-00005     Document Type: Review

References (119)

1. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990 Dec; 82 (6): 1916-24
2. Shepherd J. Lipid lowering in the elderly: Rationale and design of the PROSPER study. Cardiol Rev 2002; 19 (3 Suppl.): 16-8
3. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360 (9346): 1623-30
4. Ito H, Ouchi Y, Ohashi Y, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 2001; 8 (2): 33-44
5. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001 May 15; 134 (10): 931-40
6. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998 Nov 1; 129(9): 681-9
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285 (19): 2486-97
8. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapuetic potential in hypercholesterolaemia. Drugs 1991; 42 (1): 65-89
9. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997 Feb; 53(2): 299-336
10. O'Conner P, Feely J, Shepherd J. Lipid lowering drugs. Br Med J 1990 Mar 10; 300: 667-72
11. Alberts AW. Effects of HMG CoA reductase inhibitors on cholesterol synthesis. Drug Invest 1990; 2 Suppl. 2: 9-17
12. Glasser SP, DiBianco R, Effron BA, et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl. Am J Cardiol 1996 Jan 1; 77 (1): 83-5
13. Chan P, Lee CB, Lin TS, et al. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995 Nov; 8 (11): 1099-104
14. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994 Jun; 96 (6): 509-15
15. Morgan TO, Anderson A, Morgan O, et al. Effect of pravastatin, cholestyramine or their combination in the treatment of hypercholesterolaemia in elderly hypertensive patients. Clin Drug Invest 1995 Jun; 9 (6): 314-23
16. Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993 Aug; 102(1): 107-19
17. Yoshino G, Kazumi T, Iwai M, et al. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 1988 Jun; 71 (2-3): 95-101
18. Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514, an inhibitor of HMG-CoA reductase on serum lipids in healthy volunteers. Atherosclerosis 1986; 61: 125-8
19. Kazumi T, Yoshino G, Kasama T, et al. Effects of CS-514, a new inhibitor of HMG-CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia. Horm Metab Res 1986; 18: 654-5
20. Bard JM, Parra HJ, Douste-Blazy P, et al. Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin or cholestyramine therapy. J Drug Dev 1990; 3 suppl 1: 111-5
21. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990 Feb; 227(2): 81-94
22. Yoshino G, Matsushita M, Iwai M, et al. Two-year study on the effect of pravastatin (CS-514) on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients. Curr Ther Res 1989; 46 (1): 144-52
23. Franceschini G, Sirtori M, Vaccarino V, et al. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med 1989 Sep; 114 (3): 250-9
24. Tawata M, Miwa I, Tsuchiya K, et al. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus. Arzneimittelforschung 1995 Jun; 45 (6): 704-8
25. Yoshino G, Kazumi T, Iwai M, et al. Long-term treatment of hypercholesterolemic non-insulin dependant diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75 (1): 67-72
26. Ikeda T, Ochi H, Ohtani I, et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in non obese, non-insulin-dependant diabetes mellitus patients with hypercholesteroiemia. Curr Ther Res 1992 Apr; 51 (4): 593-9
27. Umeda F, Watanabe J, Inoue K, et al. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein a in patients with non-insulin dependant diabetes mellitus. Endocrinol Jpn 1992; 39 (1): 45-50
28. Shiomi M, Ito T, Watanabe Y, et al. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine. Atherosclerosis 1990; 83 (1): 69-80
29. Shiomi M, Ito T, Tsukada T, et al. Combination treatment with troglitazone and pravastatin suppressed atherosclerosis in WHHL rabbits [abstract no. 4.P.99]. Atherosclerosis 1997 Oct; 134 (1-2): 316-7
30. Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997 Aug; 133: 51-9
31. Sukhova GK, Williams JK, Libby P. Cholesterol-independent effects of pravastatin on atherosclerotic plaque stability in primates [abstract no. 2.P.85]. Atherosclerosis 1997 Oct; 134 (1-2): 134
32. Baldassarre D, Veglia F, Gobbi C, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis italian ultrasound study. Atherosclerosis 2000 Aug; 151: 575-83
33. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 1995; 117 (2): 225-36
34. Veglia F, Mercuri M, Gobbi C, et al. Carotid atherosclerosis progression varies according to baseline thickness in placebo and pravastatin treated subjects [abstract no. 4020]. Circulation 1997 Oct 21; 96 (8 Suppl.): 717
35. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-Mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Stalin Study (REGRESS). J Am Coll Cardiol 1998 Jun; 31 (7): 1561-7
36. Scharnagl H, Tisljar U, Gierens H, et al. Effect of pravastatin on endothelial NO-synthesis in comparison to other HMG-CoA-reductase inhibitors [abstract]. Atherosclerosis 1999 May; 144 Suppl. 1: 29
37. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999 Jan; 33 (1): 234-41
38. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999 Jun 29; 99: 3227-33
39. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994 Jun; 89 (6): 2519-24
40. Vogel RA, Corretti MC, Plotnick GD. The mechanism of improvement in endothelial function by pravastatin: direct effect or through cholesterol lowering [abstract no. 806-1]. J Am Coll Cardiol 1998 Feb; 31 (2 Suppl. A): 60A
41. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332 (8): 481-7
42. Stein JH, Carlsson CM, Papcke-Benson K, et al. The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia. J Am Coll Cardiol 2001; 38 (7): 1806-13
43. Solheim S, Seljeflot I, Arnesen H, et al. Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 2001 Aug; 157 (2): 411-5
44. D'Agate DJ, Feldman D, Dangas G, et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect [abstract no. TCT-255]. Am J Cardiol 2000 Oct 16; 86:98
45. Xiang JX, Wang YC, Lam JYT. Fibrinogen level, platelet-thrombosis and the effect of pravastatin treatment [abstract no. 217]. Can J Cardiol 1999 Sep; 15 Suppl. D: 163
46. Xiang JX, Lam JYT. Is inhibition of platelet thrombosis with pravastatin related to cholesterol reduction? [abstract no. 90]. Can J Cardiol 1998 Sep; 14 Suppl. F: 103
47. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995 Dec 1; 92 (11): 3172-7
48. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999 Apr; 33 (5): 1294-304
49. Dangas G, Ambrose JA, Smith DA, et al. Treatment of hypercholesterolemic patients with and without coronary artery disease with pravastatin decreases thrombus formation under dynamic flow conditions [abstract no. 236]. J Am Coll Cardiol 1998 Apr; 31 Suppl. C: 24-5
50. Statin therapy inhibits thrombin generation. Inpharma 1999 May 15; 1187: 19
51. Tsuda Y, Satoh K, Kitadai M, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122 (2): 225-33
52. Tsuda Y, Satoh K, Takahashi T, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993 Dec; 12 (4): 360-4
53. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001 Apr 17; 103: 1933-5
54. Simpson RJ. Placing PRINCE in perspective. JAMA 2001 Jul 4; 286 (1): 91-3
55. Ridker PM, Albert MA, Danielson E, et al. The pravastatin inflammation/CRP evaluation (PRINCE) [abstract]. J Am Coll Cardiol 2001 Sep; 38 (3): 610
56. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators [abstract no. 763]. Eur Heart J 1999 Aug-1999 30: 20 ((abstract Suppl.)): 125
57. Chan P, Lin TZ, Tomlinson B. Beneficial effects on fasting hyperinsulinemia by low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy [abstract]. 6th International Congress on Cardiovascular Pharmacotherapy; 1996 Feb 26-29; Sydney, A20
58. Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990 Jul 26; 323 (4): 224-8
59. Napoli C, Leccese M, Palumbo G, et al. Effects of vitamin E and HMG-CoA reductase inhibition on cholesterol ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis 1998; 9 (5): 257-64
60. Tsujita Y, Kuroda M, Shimada Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effects on various animal species. Biochim Biophys Acta 1986; 877 (1): 50-60
61. Koga T, Shimada Y, Kuroda M, et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 115-20
62. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997 May; 32 (5): 403-25
63. Koga K, Fukuda K, Shimada Y, et al. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de nono synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 1992; 209: 315-9
64. Yamazaki M, Suzuki H, Hanano M, et al. Na+-independant multispecific anion transporter mediates active transport of pravastatin in rat liver. Am J Physiol 1993; 264 (1 pt 1): G36-44
65. Ziegler K, Stunkel W. Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independant bile acid transporter. Biochim Biophys Acta 1992; 1139 (3): 203-9
66. Joshi HN, Fakes MG, Serajuddin ATM. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun 1999 Apr; 5: 269-71
67. Green D, O'Driscoll G, Rankin JM, et al. Beneficial effect of vitamin E administration on nitric oxide function in subjects with hypercholesterolaemia. Clin Sci 1998; 95: 361-7
68. Stein EA, Lane MC, Villanueva J, et al. Effects of statins on plasma fibrinogen [abstract]. 13th International Symposium on Drugs Affecting Lipid Metabolism; 1998 30 May
69. Tokgozoglu L, Koylan N, Soydan I, et al. Effects of low dose pravastatin therapy on endothelium generated mediators and thrombotic tendency in patients with hypercholesterolaemia [abstract no. P974]. Eur Heart J 2000; 21 (Abstract Suppl.): 156
70. Gullace G, Laface MA. Effect of pravastatin on thrombogenicfibrinolytic parameters in hypercholesterolemic patients abstract no. 1141-12]. J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 318
71. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002 Jul; 40: 67-73
72. Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27 (2): 94-103
73. Singhvi SM, Pan HY, Morrison RA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29 (2): 239-43
74. Pan HY, Willard DA, Funke PT, et al. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects. Paoletti R. Kritchevsky D, Holmes WL. Drugs affecting lipid metabolism. Berlin: Springer-Verlag, 1987: 255-9
75. Tobert SA, Shear CL, Chremos AN, et al. Clinical experience with lovastatin. Am J Cardiol 1990 Mar; 65: 23F-6F
76. Pan HY, Triscari J, DeVault AR, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991 Jun; 31 (6): 665-70
77. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990 Aug; 48 (2): 201-7
78. Pan HY, DeVault AR, Wang-Iverson D. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-35
79. Pan HY, Waclawski AP, Funke PT, et al. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993 Sep; 27 (9): 1029-33
80. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31 (6): 291-4
81. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40 (Suppl. 1): S15-8
82. Merck and co. Mevacor (lovastatin) [online]. Available from URL: http://www.merck.com [Accessed 2003 Oct 16]
83. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24 (3): 195-202
84. Botti RE, Triscari J, Pan HY, et al. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991; 14 (3): 256-61
85. Kitazawa E, Tamura N, Iwabuchi H, et al. Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxyl group of pravastatin sodium. Biochem Biophys Res Commun 1993 Apr; 192 (2): 597-602
86. Everett DW, Chando TJ, Didonato GC, et al. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991; 19 (4): 740-8
87. Halstenson CE, Triscari J, DeVault A, et al. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992 Feb; 32 (2): 124-32
88. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993 Aug; 25 (4): 2732-4
89. Bristol Myers Squibb Company. Pravachol (pravastain sodium) tablets: US prescribing information [online]. Available from URL: http://www.bms.com [Accessed 2003 Oct 16]
90. Meyer BH, Scholtz HE, Muller FD, et al. Lack of interaction between ramapril and simvastatin. Eur J Clin Pharmacol 1994; 47: 373-5
91. Becquemont L, Funck-Brenatano C, Jaillon P. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Fundam Clin Pharmacol 1999; 13 (2): 232-6
92. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998 Oct; 64 (4): 369-77
93. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40 (3): 316-23
94. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002 Feb; 36: 288-95
95. Coukell AJ, Wilde MI. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. Pharmacoeconomics 1998 Aug; 14 (2): 217-36
96. Reckless JPD. The economics of cholesterol lowering. Ballieres Clin Endocrin Metab 1990 Dec; 4 (4): 947-72
97. Simes J, Tonkin A, Kirby A, et al. Cholesterol-lowering therapy is more cost-effective for older than younger patients: results from the LIPID study [abstract no. P1528]. Eur Heart J 2001 Sep; 22 (Abstract Suppl.): 270
98. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000 May 16; 132 (10): 780-7
99. Glasziou PP, Eckermann SD, Mulray SE, et al. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Med J Aust 2002 Oct 21; 177 (8): 428-34
100. Chau J, Cheung BM, McGhee SM, et al. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J 2001 Dec; 7 (4): 360-8
101. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr; 361: 1149-58
102. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360: 7-22
103. Playford DA, Watts GF. Management of lipid disorders in the elderly. Drugs Aging 1997 Jun; 10 (6): 444-62
104. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19 (10): 1434-503
105. Aronow WS, Frishman WH. Management of hyperlipidemia in the elderly. Cardiovasc Rev Rep 2002; 23 (6): 361-70
106. Blumberger D, To TB. Treatment and management of lipid disorders in the elderly. Mature Medicine Canada 2000; 3 (4): 148-52
107. Pacala JT, McBride PE, Gray SL. Management of older adults with hypercholesterolaemia. Drugs Aging 1994; 4 (5): 366-78
108. Davidson MH, Testolin LM, Maki KC, et al. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997 Jun 9; 157(11): 1186-92
109. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolaemia: a propsective, randomized, double-blind trial. Eur. Heart J 2003; 24: 717-28
110. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993 Jan; 94 (1): 13-20
111. Aronow WS. Cholesterol 2001: Rationale for lipid-lowering in older patients with or without CAD. Geriatrics 2001 Sep; 56 (9): 22-30
112. Goldstein MR. Lovastatin versus pravastatin for hypercholesterolemia [letter]. Am J Cardiol 1994 Feb 15; 73 (5): 416
113. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double blind, 52-week trial. Am Heart J 2002 Dec; 144: 1036-43
114. Frolkis JP, Pearce GL, Nambi V, et al. Stalins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practise. Am Med J 2002 Dec 1; 113: 625-9
115. La Belle P, Davidson M, Gazdick L, et al. Efficacy of starting doses of simvastatin vs pravastatin in elderly and non-elderly patients [abstract no. 241]. Atherosclerosis 1994 Sep 15; 109: 320
116. Stefanec T. The PROSPER trial [letter]. Lancet 2003 Feb 1; 361: 427
117. Mascitelli L, Pezzetta F. The PROSPER trial [letter]. Lancet 2003 Feb 1; 361: 427
118. Goldstein MR. The PROSPER trial [letter]. Lancet 2003 Feb 1; 361: 427-8
119. Fiorenza AM. The PROSPER trial [letter]. Lancet 2003 Feb 1; 361: 428